166 related articles for article (PubMed ID: 33058112)
1. Using PARP Inhibitors in Frontline Maintenance Therapy for Ovarian Cancer.
Oncology (Williston Park); 2020 Oct; 34(10):442-444. PubMed ID: 33058112
[TBL] [Abstract][Full Text] [Related]
2. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
Parkes EE; Kennedy RD
Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
[TBL] [Abstract][Full Text] [Related]
3. PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.
Smith HJ; Walters Haygood CL; Arend RC; Leath CA; Straughn JM
Gynecol Oncol; 2015 Oct; 139(1):59-62. PubMed ID: 26303225
[TBL] [Abstract][Full Text] [Related]
4. The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 2: extending the scope beyond olaparib and BRCA1/2 mutations.
Miller RE; Ledermann JA
Clin Adv Hematol Oncol; 2016 Sep; 14(9):704-11. PubMed ID: 27673289
[TBL] [Abstract][Full Text] [Related]
5. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
6. [PARP inhibitors in first-line of ovarian cancers].
Rodrigues M
Bull Cancer; 2020 Jan; 107(1):4-5. PubMed ID: 31928735
[No Abstract] [Full Text] [Related]
7. PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond.
Banerjee S; Kaye S
Curr Oncol Rep; 2011 Dec; 13(6):442-9. PubMed ID: 21913063
[TBL] [Abstract][Full Text] [Related]
8. A universal genetic testing initiative for patients with high-grade, non-mucinous epithelial ovarian cancer and the implications for cancer treatment.
Bednar EM; Oakley HD; Sun CC; Burke CC; Munsell MF; Westin SN; Lu KH
Gynecol Oncol; 2017 Aug; 146(2):399-404. PubMed ID: 28610746
[TBL] [Abstract][Full Text] [Related]
9. Rucaparib in ovarian cancer: extending the use of PARP inhibitors in the recurrent disease.
Dal Molin GZ; Westin SN; Coleman RL
Future Oncol; 2018 Dec; 14(30):3101-3110. PubMed ID: 30105925
[TBL] [Abstract][Full Text] [Related]
10. Further Analyses Highlight Benefits of PARP Inhibitors As Frontline Maintenance in Ovarian Cancer.
Wright KM
Oncology (Williston Park); 2020 May; 34(5):175. PubMed ID: 32644177
[TBL] [Abstract][Full Text] [Related]
11. [Abnormalities of DNA repair and gynecological cancers].
Auguste A; Leary A
Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
[TBL] [Abstract][Full Text] [Related]
12. PARP inhibitors in older patients with ovarian and breast cancer: Young International Society of Geriatric Oncology review paper.
Liposits G; Loh KP; Soto-Perez-de-Celis E; Dumas L; Battisti NML; Kadambi S; Baldini C; Banerjee S; Lichtman SM
J Geriatr Oncol; 2019 Mar; 10(2):337-345. PubMed ID: 30333088
[TBL] [Abstract][Full Text] [Related]
13. Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.
Eoh KJ; Kim HM; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
BMC Cancer; 2020 Mar; 20(1):204. PubMed ID: 32164585
[TBL] [Abstract][Full Text] [Related]
14. Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer.
George A; Kaye S; Banerjee S
Nat Rev Clin Oncol; 2017 May; 14(5):284-296. PubMed ID: 27958297
[TBL] [Abstract][Full Text] [Related]
15. Incorporating PARP-inhibitors into clinical routine: A tailored treatment strategy to tackle ovarian cancer.
De Jaeghere E; Vandecasteele K; Claes K; Makar A; Tummers P; Cocquyt V; Denys H
Acta Clin Belg; 2017 Feb; 72(1):6-11. PubMed ID: 27267353
[TBL] [Abstract][Full Text] [Related]
16. [Oncogenetics in the management of ovarian cancer: State-of-the art].
Caron O
Gynecol Obstet Fertil; 2015 May; 43(5):335-7. PubMed ID: 25824714
[No Abstract] [Full Text] [Related]
17. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Moore K; Colombo N; Scambia G; Kim BG; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee S; Oza A; González-Martín A; Aghajanian C; Bradley W; Mathews C; Liu J; Lowe ES; Bloomfield R; DiSilvestro P
N Engl J Med; 2018 Dec; 379(26):2495-2505. PubMed ID: 30345884
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy directly followed by poly(ADP-ribose) polymerase inhibition as an alternative to surgery in patients with BRCA-mutated ovarian cancer: a potential management strategy in the era of coronavirus disease 2019.
Vetter MH; Smrz SA; Copeland LJ; Cohn DE
Am J Obstet Gynecol; 2020 Sep; 223(3):469-470. PubMed ID: 32454030
[No Abstract] [Full Text] [Related]
19. PARP Inhibitors for Cancer Therapy.
Lin KY; Kraus WL
Cell; 2017 Apr; 169(2):183. PubMed ID: 28388401
[TBL] [Abstract][Full Text] [Related]
20. [Poly(ADP-ribose) polymerase (PARP) inhibitors in BRCA1/2 cancer therapy].
Kluzek K; Białkowska A; Koczorowska A; Zdzienicka MZ
Postepy Hig Med Dosw (Online); 2012 Jun; 66():372-84. PubMed ID: 22706123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
